Alembic Pharmaceuticals share price
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Alembic Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2011
Last close ₹766.90up ₹0.50 (0.07%)BSE ₹770.95
Share price at the NSE close on 27 Oct 2026. Previous close ₹766.40.
27 Oct: open ₹762.55, high ₹779.00, low ₹761.80
52-week range of traded prices to 27 Oct 2026
₹635.80Low, 23 Mar 2026₹998.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,074 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.66
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.56%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,03,14164.9% delivered
Results
Consolidated; ₹ crore.Alembic Pharmaceuticals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +14.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +14.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,150 Crup 16.35%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹172 Crdown 14.48%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 8.0%
Revenue by quarter
Peak revenue ₹2,150 Cr, quarter to Jun 2026; lowest ₹1,648 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Net profit | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| Net margin | 9.3% | 8.1% | 8.9% | 9.0% | 9.6% | 7.0% | 10.9% | 8.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹7,345 Crup 10.08%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹671 Crup 15.26%
- Net margin
- 9.1%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,135what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹29 crore, a tax on the goods the company makes that it collects and pays to the government. | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 |
| Net profit | 403 | 413 | 583 | 801 | 1,147 | 521 | 342 | 616 | 582 | 671 |
| Net margin | 12.9% | 13.2% | 14.8% | 17.4% | 21.3% | 9.8% | 6.1% | 9.9% | 8.7% | 9.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Alembic Pharmaceuticals PE ratio and valuation
Price to earnings
At or below today's level on 32% of 2,228 trading days over the last 10 years.
LowestHighest
Its median25.84Industry median28.51
Price to book
At or below today's level on 14% of 1,986 trading days since Oct 2018.
LowestHighest
Its median3.54Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 77% of 2,444 trading days over the last 10 years.
LowestHighest
Its median1.04%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −26.9% | +15.7% | −38.3% | 1.8% |
| 3 years | +11.5% | +25.4% | −12.2% | 1.4% |
| 5 years | −5.7% | −10.8% | +4.0% | 1.5% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Mutual fund holdings
31 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 13 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 31 funds holding Alembic Pharmaceuticals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 9
- CutCut. Funds that held fewer shares than at the end of the month before.
- 4
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 15
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 Kotak-Small Cap FundKotak Mahindra Mutual Fund | 34,27,766 | 1.48% | ₹282.9 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 20,77,449 | 2.50% | ₹171.5 Cr |
 DSP Small Cap FundDSP Mutual Fund | 15,00,000 | 0.58% | ₹123.8 Cr |
 Axis Small Cap FundAxis Mutual Fund | 14,55,416 | 0.39% | ₹120.1 Cr |
| DSP Healthcare FundDSP Mutual Fund | 14,42,516 | 3.18% | ₹119.1 Cr |
| DSP ELSS Tax Saver FundDSP Mutual Fund | 14,34,898 | 0.76% | ₹118.4 Cr |
| DSP Aggressive Hybrid FundDSP Mutual Fund | 7,99,463 | 0.58% | ₹66.0 Cr |
| ICICI Prudential Manufacturing FundICICI Prudential Mutual Fund | 7,36,850 | 0.88% | ₹60.8 Cr |
 Abakkus Small Cap FundAbakkus Mutual Fund | 5,53,810 | 1.41% | ₹45.7 Cr |
 UTI Large & Mid Cap FundUTI Mutual Fund | 5,32,215 | 0.71% | ₹43.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Alembic Pharmaceuticals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group6 purchases, 0 sales₹20 CrNo saleNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.₹20 Cr
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Alembic Pharmaceuticals competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Alembic Pharmaceuticals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Alivus Life SciencesALIVUS | 16,496 | 27.35 | 4.95 | +7.9% | +21.7% | 19.6% | 22.7% | 0.37% |
 Natco PharmaNATCOPHARM | 15,587 | 13.62 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Jubilant PharmovaJUBLPHARMA | 15,288 | 43.42 | 2.16 | +16.3% | −23.5% | 5.3% | 7.3% | 0.52% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,183 | 89.51 | 17.40 | +31.1% | −7.5% | 20.6% | 24.4% | 0.59% |
 Concord BiotechCONCORDBIO | 14,388 | 50.94 | 6.93 | +4.0% | −12.8% | 14.5% | 15.9% | 0.55% |
 Marksans PharmaMARKSANS | 13,599 | 26.32 | 4.50 | – | – | 17.1% | 19.9% | 0.30% |
 CORONA RemediesCORONA | 13,162 | 66.13 | 17.62 | – | – | 26.6% | 30.9% | 0.46% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,321 | 38.81 | 3.42 | +9.2% | −14.6% | 9.2% | 12.0% | 0.42% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Alembic Pharmaceuticals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹18.00 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 29 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹12.00 |
| 29 Jul 2025 | Final | ₹11.00 |
| 15 Jul 2024 | Final | ₹11.00 |
| 28 Jul 2023 | Final | ₹8.00 |
| 17 Aug 2022 | Interim | ₹10.00 |
| 19 Jul 2021 | Final | ₹14.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Alembic Pharmaceuticals announcements
Oct 2026
19 Oct
Sep 2026
18 Sep · Analysts
Alembic Pharmaceuticals share price by year
Each calendar year to 2025.Alembic Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 846.15 | −20.6% | 1,091.50 | 743.65 |
| 2024 | 1,066.25 | +40.4% | 1,247.70 | 765.90 |
| 2023 | 759.40 | +32.6% | 815.00 | 468.65 |
| 2022 | 572.90 | −28.6% | 841.25 | 543.25 |
| 2021 | 801.90 | −22.4% | 1,096.95 | 734.55 |
| 2020 | 1,033.75 | +80.9% | 1,126.70 | 445.40 |
| 2019 | 571.30 | −4.7% | 599.25 | 460.65 |
| 2018 | 599.70 | +13.0% | 654.25 | 418.15 |
| 2017 | 530.60 | −10.8% | 629.95 | 480.75 |
| 2016 | 595.10 | −14.5% | 687.85 | 527.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 759.45 | 769.55 | 753.55 | 766.40 | 764.33 | 43,824 | 44.7% |
| 23 Oct 2026 | 775.00 | 776.00 | 748.25 | 760.10 | 759.84 | 1,20,847 | 52.2% |
| 22 Oct 2026 | 779.00 | 786.95 | 777.15 | 781.30 | 781.70 | 45,524 | 58.1% |
| 21 Oct 2026 | 794.20 | 794.70 | 781.30 | 787.95 | 786.27 | 61,315 | 55.9% |
| 19 Oct 2026 | 790.05 | 799.00 | 779.00 | 790.35 | 787.83 | 1,37,411 | 68.0% |
| 16 Oct 2026 | 792.65 | 793.00 | 771.00 | 789.45 | 783.41 | 1,48,103 | 51.0% |
| 15 Oct 2026 | 797.95 | 802.40 | 789.25 | 792.65 | 795.06 | 77,862 | 56.2% |
| 14 Oct 2026 | 789.05 | 799.15 | 785.80 | 792.45 | 792.24 | 70,461 | 55.9% |
| 13 Oct 2026 | 787.10 | 800.00 | 778.85 | 797.85 | 790.99 | 70,432 | 45.5% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- APLLTD
- BSE code
- 533573
- ISIN
- INE901L01018
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.alembic-india.com
- CIN
- L24230GJ2010PLC061123
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2010
- Registered office
- Alembic Road, Vadodara 390003, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments